NCT06786286View on ClinicalTrials.gov

A Mass Balance Study Following Subcutaneous Administration of [14C]-ITI-1284 to Healthy Male Subjects

PHASE1CompletedINTERVENTIONAL
Enrollment

8

Participants

Timeline

Start Date

January 28, 2025

Primary Completion Date

March 26, 2025

Study Completion Date

March 26, 2025

Conditions
Healthy Volunteers
Interventions
DRUG

[14C]-ITI-1284

\[14C\]-ITI-1284 20 mg oral solution (not more than 22 μCi), subcutaneous administration

Trial Locations (1)

NG116JS

Clinical Site 1, Nottingham

Sponsors
All Listed Sponsors
lead

Intra-Cellular Therapies, Inc.

INDUSTRY

NCT06786286 - A Mass Balance Study Following Subcutaneous Administration of [14C]-ITI-1284 to Healthy Male Subjects | Biotech Hunter | Biotech Hunter